Targeting OR10 as A Drug Target for OR10-Linked Disorders (G390201)

Targeting OR10 as A Drug Target for OR10-Linked Disorders

Olfactory receptor family 10 (OR10) is a subfamily of the olfactory receptor family that plays a crucial role in human olfactory function. OR10 is composed of two transmembrane proteins, OR10-1 and OR10-2, which are expressed in the olfactory epithelium and are involved in the detection of volatile organic compounds (VOCs) in the air. Mutations in the OR10 gene have been linked to a range of disorders, including sensory loss, blindness, and even death. As a result, targeting OR10 has potential as a drug target for treating a variety of conditions.

The OR10 gene is located on chromosome 6p and contains three exons. The first exon encodes the N-terminus of OR10, which contains a signal transduction domain (STD) that plays a critical role in ligand binding and subsequent downstream signaling. The second exon encodes the C-terminus of OR10, which contains a putative transmembrane region (TM) that is involved in protein-protein interactions and other non-functional domains, such as a leucine zipper (LZ) and a potential G protein-coupled receptor (GPCR ) domain. The third exon encodes the Z-terminus of OR10, which is also involved in STD signaling.

OR10-1 and OR10-2 are involved in the detection of VOCs in the air and are expressed in the olfactory epithelium, which is the lining of the olfactory organs (such as the nose and mouth). They function as a two-component system , with OR10-1 and OR10-2 forming a complex that is responsible for the detection of VOCs. OR10-1 is the catalytic subunit of the enzyme OR10-1-linked receptor, while OR10-2 is a ligand-gated receptor that activates in response to specific VOCs.

Mutations in the OR10 gene have been linked to a range of disorders, including sensory loss, blindness, and even death. For example, a missense mutation in the OR10 gene has been linked to a condition called agromontanism, which is characterized by the loss of sense of smell and vision. In addition, mutations in the OR10 gene have also been linked to other disorders, including cancer, neurodegenerative diseases, and developmental disorders.

Targeting OR10 has potential as a drug target because it is involved in the detection of a wide variety of VOCs, including volatile organic compounds (VOCs) that are often associated with neurological and psychiatric disorders. For example, OR10 is involved in the detection of ammonia, which has been linked to various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic neurodegenerative disorders. In addition, OR10 is also involved in the detection of other VOCs, such as acetone, which has been linked to cancer and other neurodegenerative diseases.

Targeting OR10 has also been shown to be effective in treating a variety of disorders, including sensory loss and cancer. For example, a drug that targets OR10, called OR10-18, has been shown to protect against the development of neurodegenerative diseases in animal models . In addition, a drug that targets OR10, called NX-525, has been shown to be an effective treatment for sensory loss in animal models.

In conclusion, OR10 is a subfamily of the olfactory receptor family that plays a crucial role in human olfactory function. Mutations in the OR10 gene have been linked to a range of disorders, including sensory loss, blindness, and even death. Targeting OR10 has potential as a drug target for treating a variety of conditions, including sensory loss, cancer, and neurodegenerative diseases. Further research is needed to fully understand the role of OR10 in human

Protein Name: Olfactory Receptor Family 10 Subfamily V Member 1

Functions: Odorant receptor

The "OR10V1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR10V1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3